aTyr Pharma
ATYR
45 hedge funds and large institutions have $58.1M invested in aTyr Pharma in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 3 closing their positions.
200% more call options, than puts
Call options by funds: $3K | Put options by funds: $1K
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
13% more funds holding
Funds holding: 40 → 45 (+5)
6.02% more ownership
Funds ownership: 64.35% → 70.38% (+6%)
1% less capital invested
Capital invested by funds: $58.7M → $58.1M (-$565K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.5M |
| 2 |
Renaissance Technologies
New York
|
+$477K |
| 3 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$305K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$291K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$5.32M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$121K |
| 3 |
Two Sigma Investments
New York
|
-$84.4K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$56.9K |
| 5 |
Two Sigma Advisers
New York
|
-$53.2K |
ATYR Hedge Fund Activity: Q4 2023 in Review
45 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2023, worth a combined $58.1M — down 0.96% from $58.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ATYR positions and 3 closed out — a net gain of 5 holders — while 15 added to existing stakes and 10 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $7.5M. The largest seller was Stonepine Capital Management, cutting an estimated $5.32M.
- 45 institutional investors held aTyr Pharma (ATYR) as of Q4 2023, up from 40 in Q3 2023.
- Funds reported $58.1M of aTyr Pharma stock for Q4 2023, down 0.96% quarter-over-quarter.
- 8 funds opened new aTyr Pharma positions in Q4 2023 and 3 closed out, a net change of +5 holders.
- The largest aTyr Pharma buyer in Q4 2023 was Logos Global Management, an estimated $7.5M added.
- The largest aTyr Pharma seller in Q4 2023 was Stonepine Capital Management, an estimated $5.32M sold.
Based on aggregated 13F filings for Q4 2023.